Human Papillomavirus Minor Capsid Protein L2 (L2) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Human Papillomavirus Minor Capsid Protein L2 (L2) – Pipeline Review, H1 2017’, provides in depth analysis on Human Papillomavirus Minor Capsid Protein L2 (L2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Human Papillomavirus Minor Capsid Protein L2 (L2)Additionally, the report provides an overview of key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Infectious Disease under development targeting Human Papillomavirus Minor Capsid Protein L2 (L2)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)

The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Agilvax Inc

Cancer Research Technology Ltd

Pathovax LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview

Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development

Agilvax Inc

Cancer Research Technology Ltd

Pathovax LLC

Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles

AX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products

Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones

Featured News & Press Releases

Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest

Sep 06, 2016: Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate

Feb 03, 2015: Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus

Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine

Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Agilvax Inc, H1 2017

Pipeline by Cancer Research Technology Ltd, H1 2017

Pipeline by Pathovax LLC, H1 2017

Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports